Urokinase Plasminogen Activator Secreted by Cancer-Associated Fibroblasts Induces Tumor Progression Via PI3K/AKT and ERK Signaling in Esophageal Squamous Cell Carcinoma.

Baoqing Tian,Xiaojia Chen,Huihua Zhang,Xiaoyan Li,Jiakang Wang,Wei Han,Li-Yi Zhang,Li Fu,Yan Li,Changjun Nie,Ying Zhao,Xuan Tan,Hailong Wang,Xin-Yuan Guan,An Hong
DOI: https://doi.org/10.18632/oncotarget.15857
2017-01-01
Oncotarget
Abstract:Cancer-associated fibroblasts (CAFs) are believed to influence tumor behavior and clinical outcomes. We previously showed that conditioned medium (CM) from CAFs induces proliferation and motility of esophageal squamous cell carcinoma (ESCC) cells. Here, we investigated the molecular mechanisms by which the CAF-secreted proteins induce ESCC development and progression. Using antibody arrays, we identified urokinase plasminogen activator (uPA) as one of the main proteins whose release was increased in CAFs compared to normal fibroblasts (NFs). Immunohistochemical analysis of pathological sections showed that uPA-positive cells were localized at the boundaries of tumor and stroma tissues, in stroma between tumor nests, and within the tumors. Increased stromal uPA levels (132/146 cases) correlated with tumor invasion (p < 0.05) and overall survival of ESCC patients (p < 0.05). In vitro assays showed that uPA promotes ESCC cell proliferation, migration, and invasion via PI3K/AKT and ERK signaling pathways. In vivo, anti-uPA antibody suppressed tumor growth in ESCC xenografts. These results suggest that uPA released from stroma, and especially from CAFs, might be a predictive marker for ESCC diagnosis and prognosis, as well as an effective therapeutic target.
What problem does this paper attempt to address?